Field guide · /learn/reading-research

Research & evidence · Sources checked Nov 6, 2026

How to read psychedelic research and dosing evidence

What clinical milligram doses mean, how trials differ from informal use, and how to interpret study claims without hype.

key facts

Start here

  • › Modern trials often use a known milligram dose of purified/synthetic psilocybin — not a weighed pile of dried mushrooms of unknown potency.
  • › Preparation, monitoring, and integration are part of the studied intervention, not optional extras.
  • › Open-label results and small samples can overstate certainty; look for controls, blinding, and follow-up length.
  • › Research findings are not personal medical advice and do not make possession legal.

The short answer

Clinical psychedelic studies usually dose a known milligram amount of purified or synthetic psilocybin in a controlled setting with preparation and monitoring. That is a different object than “2 grams of dried mushrooms from a jar,” because dried material varies in alkaloid content. Promising trial results are not FDA approval, not personal medical advice, and not a change to federal legality.

Milligrams in trials vs grams on the street

Johns Hopkins Medicine summaries of major depression research describe supervised psilocybin sessions with supportive psychotherapy and structured follow-up — not informal self-experimentation. Imperial College / related imaging work similarly reports oral psilocybin protocols (including 25 mg arms in comparative trials) with neuroimaging endpoints.

When educational tools translate clinical milligrams into approximate dried-mushroom grams, they must assume an average potency. Real samples deviate. See Potency & lab tests and the Dosage calculator notes.

A practical checklist for study claims

  1. Population — healthy volunteers, treatment-resistant depression, PTSD, end-of-life anxiety? Results may not transfer.
  2. Dose and form — synthetic/purified mg vs mushroom material; number of sessions.
  3. Support package — preparation, sitters/therapists, integration. The drug is not studied in a vacuum.
  4. Controls — placebo, active comparator, blinding quality. Expectancy effects are a known challenge.
  5. Follow-up length — days vs months. Early mood lifts can fade; durable claims need durable data.
  6. Conflicts and sponsorship — read funding and author disclosures on the paper or trial registry.

What research evidence is not

  • Not a guarantee of benefit for any individual.
  • Not proof that unsupervised use is safe.
  • Not legal authorization — U.S. federal Schedule I status still applies outside regulated pathways.
  • Not a substitute for clinicians, especially with psychiatric history or interacting medications.
Educational only. For harm-reduction framing see Safety; for policy context see Legal; for clinical-program landscape see Therapeutic research.

faq

Common questions

Why do studies talk about 25 mg of psilocybin instead of grams of mushrooms?

Clinical protocols dose a measured amount of the active compound. Dried mushrooms vary in tryptamine content, so a gram weight is not equivalent to a known milligram dose unless the material is assayed.

Does a positive trial mean mushrooms are safe or approved medicine?

No. Promising evidence for specific conditions under medical supervision is not the same as FDA approval or a green light for unsupervised use. Risks, screening, and legal status still apply.

How should I treat dosage calculators?

As educational ranges tied to research-style fixed doses and average potency assumptions — not a prescription. Potency variance and individual factors make any gram estimate uncertain.

related records

Trusted resources: Johns Hopkins Center for Psychedelic Research · MAPS · UC Berkeley Center for the Science of Psychedelics · DanceSafe · Zendo Project · Fireside Project